Chen Yidi, Chen Jie, Yang Chongtu, Wu Yuanan, Wei Hong, Duan Ting, Zhang Zhen, Long Liling, Jiang Hanyu, Song Bin
Department of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China.
Big Data Research Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Insights Imaging. 2023 Nov 14;14(1):190. doi: 10.1186/s13244-023-01539-x.
Hepatocellular carcinoma (HCC) expressing cytokeratin (CK) 7 or CK19 has a cholangiocyte phenotype that stimulates HCC proliferation, metastasis, and sorafenib therapy resistance This study aims to noninvasively predict cholangiocyte phenotype-positive HCC and assess its prognosis after hepatectomy.
Between January 2010 and May 2022, preoperative contrast-enhanced MRI was performed on consecutive patients who underwent hepatectomy and had pathologically confirmed solitary HCC. Two abdominal radiologists separately assessed the MRI features. A predictive model for cholangiocyte phenotype HCC was created using logistic regression analysis and five-fold cross-validation. A receiver operating characteristic curve was used to calculate the model performance. Kaplan-Meier and log-rank methods were used to evaluate survival outcomes.
In total, 334 patients were included in this retrospective study. Four contrast-enhanced MRI features, including "rim arterial phase hyperenhancement" (OR = 5.9, 95% confidence interval [CI]: 2.9-12.0, 10 points), "nodule in nodule architecture" (OR = 3.5, 95% CI: 2.1-5.9, 7 points), "non-smooth tumor margin" (OR = 1.6, 95% CI: 0.8-2.9, 3 points), and "non-peripheral washout" (OR = 0.6, 95% CI: 0.3-1.0, - 3 points), were assigned to the cholangiocyte phenotype HCC prediction model. The area under the curves for the training and independent validation set were 0.76 and 0.73, respectively. Patients with model-predicted cholangiocyte phenotype HCC demonstrated lower rates of recurrence-free survival (RFS) and overall survival (OS) after hepatectomy, with an estimated median RFS and OS of 926 vs. 1565 days (p < 0.001) and 1504 vs. 2960 days (p < 0.001), respectively.
Contrast-enhanced MRI features can be used to predict cholangiocyte phenotype-positive HCC. Patients with pathologically confirmed or MRI model-predicted cholangiocyte phenotype HCC have a worse prognosis after hepatectomy.
Four contrast-enhanced MRI features were significantly associated with cholangiocyte phenotype HCC and a worse prognosis following hepatectomy; these features may assist in predicting prognosis after surgery and improve personalized treatment decision-making.
• Four contrast-enhanced MRI features were significantly associated with cholangiocyte phenotype HCC. • A noninvasive cholangiocyte phenotype HCC predictive model was established based on MRI features. • Patients with cholangiocyte phenotype HCC demonstrated a worse prognosis following hepatic resection.
表达细胞角蛋白(CK)7或CK19的肝细胞癌(HCC)具有胆管细胞表型,可刺激HCC增殖、转移及对索拉非尼治疗产生耐药性。本研究旨在无创预测胆管细胞表型阳性的HCC,并评估肝切除术后其预后情况。
2010年1月至2022年5月期间,对连续接受肝切除术且病理确诊为孤立性HCC的患者进行术前对比增强MRI检查。两名腹部放射科医生分别评估MRI特征。采用逻辑回归分析和五折交叉验证创建胆管细胞表型HCC的预测模型。使用受试者工作特征曲线计算模型性能。采用Kaplan-Meier法和对数秩检验评估生存结果。
本回顾性研究共纳入334例患者。四个对比增强MRI特征,包括“边缘动脉期强化”(OR = 5.9,95%置信区间[CI]:2.9 - 12.0,10分)、“结节内结节结构”(OR = 3.5,95% CI:2.1 - 5.9,7分)、“肿瘤边缘不光滑”(OR = 1.6,95% CI:0.8 - 2.9,3分)和“非周边廓清”(OR = 0.6,95% CI:0.3 - 1.0, - 3分),被纳入胆管细胞表型HCC预测模型。训练集和独立验证集的曲线下面积分别为0.76和0.73。模型预测为胆管细胞表型HCC的患者肝切除术后无复发生存(RFS)和总生存(OS)率较低,估计中位RFS和OS分别为926天对1565天(p < 0.001)和1504天对2960天(p < 0.001)。
对比增强MRI特征可用于预测胆管细胞表型阳性的HCC。病理确诊或MRI模型预测为胆管细胞表型HCC的患者肝切除术后预后较差。
四个对比增强MRI特征与胆管细胞表型HCC及肝切除术后较差预后显著相关;这些特征可能有助于预测术后预后并改善个性化治疗决策。
• 四个对比增强MRI特征与胆管细胞表型HCC显著相关。• 基于MRI特征建立了无创胆管细胞表型HCC预测模型。• 胆管细胞表型HCC患者肝切除术后预后较差。